Immunomodulation Is the Key to Cardiac Repair

Hamid, Tariq; Prabhu, Sumanth D.

doi:10.1161/circresaha.117.310954

Cited by 22 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs not only act by producing proregenerative paracrine factors, but also have immunomodulatory properties by interacting directly and indirectly with cells of the immune system 107 . Since sustained chronic inflammation is a typical aspect of ischemic cardiomyopathy leading to adverse ventricular remodeling, suppression of the inflammatory response may be indeed an effective strategy to promote cardiac repair 110 . Luger et al showed that intravenous administration of MSCs in mice with acute MI attenuates neutrophil and natural killer cell responses.…”

Section: Stem Cell Types For Myocardial Repairmentioning

confidence: 99%

Combining stem cells in myocardial infarction: The road to superior repair?

Beliën

Evens

Hendrikx

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Myocardial infarction irreversibly destroys millions of cardiomyocytes in the ventricle, making it the leading cause of heart failure worldwide. Over the past two decades, many progenitor and stem cell types were proposed as the ideal candidate to regenerate the heart after injury. The potential of stem cell therapy has been investigated thoroughly in animal and human studies, aiming at cardiac repair by true tissue replacement, by immune modulation, or by the secretion of paracrine factors that stimulate endogenous repair processes. Despite some successful results in animal models, the outcome from clinical trials remains overall disappointing, largely due to the limited stem cell survival and retention after transplantation. Extensive interest was developed regarding the combinational use of stem cells and various priming strategies to improve the efficacy of regenerative cell therapy. In this review, we provide a critical discussion of the different stem cell types investigated in preclinical and clinical studies in the field of cardiac repair. Moreover, we give an update on the potential of stem cell combinations as well as preconditioning and explore the future promises of these novel regenerative strategies.

show abstract

Section: Stem Cell Types For Myocardial Repairmentioning

confidence: 99%

Combining stem cells in myocardial infarction: The road to superior repair?

Beliën

Evens

Hendrikx

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…SCs possess a paracrine activity capable of modulate the immune system and reduce inflammation processes, allowing tissue restoration in damaged zones. This paracrine capability is due to the constitutive secretion of anti-inflammatory factors in extracellular vesicles 6 , among which are cytokines with anti-inflammatory capabilities such as prostaglandin 2, interleukin 10, and the granulocyte colony-stimulating factor 7 , as well as factors with the ability to change the macrophages M1 pro-inflammatory phenotype to M2 anti-inflammatory phenotype 8 and suppress the activation of neutrophils, dendritic cells, NK cells, and T cells 9 . All this, allows for its potential use in degenerative diseases linked to autoimmune disorders, such as Crohn's disease, systemic erythematous lupus, and transplant rejection 10 , including central nervous system disorders mediated by the abnormal activation of glial cells and immune infiltration 11 , being able to moderate neuronal loss in diseases such as amyotrophic lateral sclerosis and Alzheimer's and Parkinson's diseases.…”

Section: Immunomodulator Propertiesmentioning

confidence: 99%

Therapeutic use of stem cells in Mexico: Status and perspectives

García-Ruiz¹,

Sánchez‐Domínguez²

2021

RMU

View full text Add to dashboard Cite

The use of stem cells (SCs) is one of the most promising strategies for multiple human affections due to its properties such as proliferation, migration through the tissue, immune system modulation, and differentiation potential. SC can differentiate into the cellular lineages of the organism, which gives them a potential use for restoration of damaged tissue due to acute or chronic factors and immune diseases. Due to these properties, SC has been evaluated in more than 6700 clinical trials worldwide, including Mexico. Actual research has not clarified all the biological mechanisms that control SCs so that there are multiple risks involved in SC treatments, which patients need to consider before approaching said treatments. There is also a lack of legislation for these treatments, which despite having a real potential therapeutic effect, propitiates the establishment of medical treatments that do not guarantee safety and efficacy, so patients should consider the risks and benefits before a procedure. This review intends to provide an overview of SC characteristics, identification, actual and future SC treatments, and information about non-regulated SC therapies and possible side effects.

show abstract

“…Following the early inflammation stage, pathophysiological changes in MIRI might next cause endogenous signals that may trigger anti-inflammatory phases dominated by the innate immune response [82, 83], the transitional stage of which may involve a sophisticated interaction between cardiac cells and components of the immune response [84, 85]. Since the cellular immune response and inflammatory microenvironment can, to a large extent, trigger adverse cardiac remodeling in MIRI patients [84, 86]; researchers and clinicians have been trying to identify potential therapeutic molecular and cellular targets for AMI from the perspective of both the innate and adaptive immune systems [85, 87]. For example, through in vitro and in vivo experiments, several protective cell types of the immune system have been found to actively respond to MIRI, including pericytes, Ly6C high monocytes, M2 macrophages, and CD8 + /AGTR2 + T cells [85–89].…”

Section: Immunoreaction Of Mirimentioning

confidence: 99%

“…Since the cellular immune response and inflammatory microenvironment can, to a large extent, trigger adverse cardiac remodeling in MIRI patients [84, 86]; researchers and clinicians have been trying to identify potential therapeutic molecular and cellular targets for AMI from the perspective of both the innate and adaptive immune systems [85, 87]. For example, through in vitro and in vivo experiments, several protective cell types of the immune system have been found to actively respond to MIRI, including pericytes, Ly6C high monocytes, M2 macrophages, and CD8 + /AGTR2 + T cells [85–89].…”

Section: Immunoreaction Of Mirimentioning

confidence: 99%

Novel Molecular Targets Participating in Myocardial Ischemia-Reperfusion Injury and Cardioprotection

Liu

Chen

et al. 2019

Cardiology Research and Practice

View full text Add to dashboard Cite

Worldwide morbidity and mortality from acute myocardial infarction (AMI) and related heart failure remain high. While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical treatment at present, collateral myocardial ischemia-reperfusion injury (MIRI) and pertinent cardioprotection are still challenging to address and have inadequately understood mechanisms. Therefore, unveiling the related novel molecular targets and networks participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier. The present study specifically focuses on the recent MIRI advances that are supported by sophisticated bio-methodology in order to bring the poorly understood interrelationship among pro- and anti-MIRI participant molecules up to date, as well as to identify findings that may facilitate the further investigation of novel targets.

show abstract

Immunomodulation Is the Key to Cardiac Repair

Cited by 22 publications

References 15 publications

Combining stem cells in myocardial infarction: The road to superior repair?

Combining stem cells in myocardial infarction: The road to superior repair?

Therapeutic use of stem cells in Mexico: Status and perspectives

Novel Molecular Targets Participating in Myocardial Ischemia-Reperfusion Injury and Cardioprotection

Contact Info

Product

Resources

About